Regulatory Update Archives

ENCELTO implant releasing neurotrophic factor

August 15, 2025

U.S. Patient Receives World’s First ENCELTO Gene Therapy for MacTel

ENCELTO officially hits the United States, offering MacTel patients a slice of hope. One small injection for a patient, one…

May 23, 2025

FDA Approves Roche’s Susvimo for Diabetic Retinopathy

Genentech/Roche’s sustained release anti-VEGF eye implant provides a treatment option with reduced frequency for diabetic retinopathy. Sustained release anti-VEGF is…

U.S. Patient Receives World’s First ENCELTO Gene Therapy for MacTel

May 23, 2025

FDA Approves Roche’s Susvimo for Diabetic Retinopathy

FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks

April 22, 2025

U.S. Patient Receives World’s First ENCELTO Gene Therapy for MacTel

FDA Approves Roche’s Susvimo for Diabetic Retinopathy

U.S. Patient Receives World’s First ENCELTO Gene Therapy for MacTel

U.S. Patient Receives World’s First ENCELTO Gene Therapy for MacTel

FDA Approves Roche’s Susvimo for Diabetic Retinopathy

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

Discover our fascinating content at issuu